Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of combining a second agent with a JAK inhibitor when treating patients with myelofibrosis (MF), and further highlights some agents being explored, including navitoclax, pelabresib, and parsaclisib. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.